223 results on '"Swiecicki, Paul L."'
Search Results
2. Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer
3. Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma
4. Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection
5. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study
6. Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma
7. Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
8. Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial of 18F-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemoradiotherapy for p16+ Oropharynx Cancer: A Planned Interim Analysis
9. Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma
10. Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma.
11. Prognostic Significance of Oxidation Pathway Mutations in Recurrent Laryngeal Squamous Cell Carcinoma
12. Follow‐up for human papillomavirus‐related oropharynx cancer concentrated on unequal symptom change (FOCUS): Prospective patient‐reported outcome collection
13. Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment
14. Prognostic value of CD103+ tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma
15. Head and Neck Cancer
16. Window of opportunity trials in head and neck cancer
17. Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials
18. Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.
19. Revisiting Expectations in an Era of Precision Oncology
20. Impact of extrinsic tongue muscle invasion on stage migration in AJCC 8th edition staging of oral cavity carcinoma
21. Patient-reported financial toxicity and adverse medical consequences in head and neck cancer
22. A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma
23. A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma
24. From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer
25. Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA
26. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life
27. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols
28. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines who are SuspectedDPYDVariant Carriers Based on a Genetic Data Repository
29. Supplementary Table 3 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
30. Supplementary Table 2 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
31. Supplementary Table 4 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
32. Supplementary table 3 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
33. Supplementary Data from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
34. Supplementary figure and table legends from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
35. Supplementary table 6 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
36. Supplementary table 2 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
37. Supplementary figure 1 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
38. Supplementary table 7 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
39. Supplementary table 4 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
40. Supplementary table 5 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
41. Supplementary table 1 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
42. Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer
43. Initial Feasibility and Acute Toxicity Outcomes from a Phase II trial of FDG-PET response-based de-escalated definitive chemoradiotherapy for p16+ oropharynx cancer, a Planned Interim Analysis
44. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
45. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
46. Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
47. Mitotic Checkpoints and the Role of WEE1 Inhibition in Head and Neck Squamous Cell Carcinoma
48. Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis
49. Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck
50. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.